Form 4: Immix Biopharma Director Carey Ng Acquires Significant Stock Options

Immix Biopharma, Inc. Director Carey Ng reported the acquisition of 33,000 stock options and updated his beneficial ownership of common stock.

Summary

• Carey Ng, a Director of Immix Biopharma, Inc. (IMMX), filed a Form 4 to report changes in his beneficial ownership.
• He acquired 33,000 stock options to purchase common stock, with an exercise price of $2.24 per share.
• The stock options were granted on June 20, 2025, and are set to expire on June 20, 2035.
• These options will vest in twelve equal monthly installments following the grant date, contingent upon Mr. Ng's continued service on the Board of Directors.
• Following this transaction, Mr. Ng directly owns 20,000 shares of Immix Biopharma common stock.
• He also indirectly beneficially owns 1,025,221 shares of common stock through Mesa Verde Venture Partners III, LP, where he serves as Managing Director.
• Mr. Ng disclaims beneficial ownership of the securities held by Mesa Verde, except to the extent of his pecuniary interest therein.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director is generally a positive signal, indicating alignment of interests and confidence in the company's future. It's not a financial performance report, so a neutral-to-positive score is appropriate.

Positives

• Director Carey Ng's acquisition of 33,000 stock options aligns his financial interests with those of the company's shareholders, indicating confidence in Immix Biopharma's future prospects.
• The vesting schedule over twelve months encourages long-term commitment and continued service from a key member of the Board of Directors.

Future Outlook

The vesting schedule of the newly acquired stock options, set over twelve equal monthly installments, indicates an expectation of Carey Ng's continued service on the Board of Directors for at least the next year, aligning his long-term interests with the company's performance.

Industry Context

This Form 4 filing is a standard disclosure for executive compensation and insider transactions within the biopharmaceutical industry, reflecting a common practice of granting stock options to directors to incentivize long-term commitment and align their interests with shareholder value creation.

Related Party Transactions

• Carey Ng's indirect beneficial ownership of 1,025,221 shares through Mesa Verde Venture Partners III, LP, where he is the Managing Director, constitutes a related party interest. He disclaims beneficial ownership except for his pecuniary interest.

Stakeholder Impact

• Shareholders: The acquisition of stock options by a director can be viewed positively as it aligns management's incentives with shareholder value creation.

Next Steps

• Continued vesting of 33,000 stock options in twelve equal monthly installments, subject to Carey Ng's continued service on the Board of Directors.

Key Dates

Keywords

Immix Biopharma, IMMX, Carey Ng, SEC Form 4, Stock Options, Beneficial Ownership, Director Compensation, Biopharma